| Literature DB >> 35801758 |
Liwen Jin1, Yiming Fang, Can Jin.
Abstract
OBJECTIVE: To assess the efficacy of binocular treatment for individual with amblyopia.Entities:
Mesh:
Year: 2022 PMID: 35801758 PMCID: PMC9259175 DOI: 10.1097/MD.0000000000028975
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1.The flow chart depicting the study selection process.
Baseline characteristics of included studies.
| Intervention group | Control group | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Year | Country | Study | Type of control group | Treat time | N | M/F | Age | N | M/F | Age | Quality |
| Li | 2014 | USA | Non-RCT | Sham games | 4 h/w for 4 weeks | 45 | 25/20 | – | 24 | 14/10 | – | 4 |
| Birch | 2015 | USA | RCT | Sham iPad games | 4 h/w for 4 weeks | 45 | – | – | 5 | – | – | 5 |
| Vedamurthy | 2015 | USA | Non-RCT | Watch movies | 1.5–2 hours, for at least 2 and up to 5 times/week, 40 hours | 23 | 9/14 | 39.6 ± 16 | 15 | 7/8 | 40.1 ± 15 | 4 |
| Holmes | 2016 | USA | Non-RCT | Patching | 16 weeks, binocular group: 1 hour a day; patching group: 2 hours a day | 190 | 92/98 | 8.4 ± 1.8 | 195 | 106/89 | 8.6 ± 2.0 | 5 |
| Kelly | 2016 | USA | RCT | Patching | 2 weeks | 14 | 11/3 | 6.60 ± 1.39 | 14 | 10/4 | 6.95 ± 1.51 | 6 |
| Gao | 2018 | Multicentre | RCT | Placebo | 6 weeks | 56 | 34/22 | 22.1 ± 13.9 | 59 | 31/28 | 21.0 ± 13.4 | 4 |
| Iwata | 2018 | Japan | RCT | Glasses treatment | 2 days a week, 30 minutes per day | 23 | – | 4.9 ± 1.1 | 23 | – | 4.8 ± 1.2 | 5 |
| Manh | 2018 | USA | RCT | Patching | 16 weeks | 40 | 24/16 | 14.3 ± 1.1 | 60 | 34/26 | 14.3 ± 1.1 | 5 |
| Holmes | 2018 | Multicentre | RCT | Continued optical treatment | 8 weeks, 1 hour a day 5 days per week | 69 | 39/30 | 9.6 ± 1.6 | 69 | 34/30 | 9.6 ± 1.5 | 5 |
| Sauvan | 2019 | France | Non-RCT | Patching | 6 sessions of 1.5 hour | 10 | – | – | 7 | – | – | 4 |
| Birch | 2020 | Texas | RCT | Current treatment only | 5 hours/week for 4 weeks | 8 | – | – | 7 | – | – | 3 |
| Pang | 2020 | China/Canada | RCT | Placebo | 6 weeks | 12 | – | – | 11 | – | – | 4 |
| Yao | 2020 | China | RCT | Patching | 3 months | 36 | 20/16 | 6.50 ± 2.81 | 38 | 14/24 | 5.95 ± 2.28 | 3 |
RCT = randomized controlled trial; M/F = male/female.
Overall and sensitivity meta-analysis results
| Outcomes | SMD/WMD (95%CI) |
| I2 |
|---|---|---|---|
| Amblyopic eye visual acuity | |||
| Overall | 0.473 (0.104,0.841) | 0.012 | 89.4 |
| Sensitivity analysis | 0.473 (0.104,0.841) | ||
| Design | |||
| RCT | 0.169 (–0.183,0.521) | 0.347 | 74 |
| Non-RCT | 0.882(0.152,1.613) | 0.018 | 94.3 |
| Best corrected visual acuity | |||
| Overall | –0.006 (–0.092,0.079) | 0.882 | 89.9 |
| Sensitivity analysis | –0.006 (–0.092,0.079) | ||
| Stereo acuity | |||
| Overall | 0.138 (0.068,0.208) | <0.001 | 65.4 |
| Sensitivity analysis | 0.138 (0.068,0.208) | ||
| Design | |||
| RCT | 0.246 (0.133,0.358) | <0.001 | 0 |
| Non-RCT | 0.092 (0.023,0.160) | 0.009 | 77.4 |
CI = confidence intervals, RCT = randomized controlled trial, SMD = standard mean difference, WMD = weighted mean difference.
Figure 2.Forest plot of comparison on the amblyopic eye visual acuity in trial group and control group. (A) overall analysis; (B) subgroup analysis based on RCTs or Non-RCTs.
Figure 3.Forest plot of comparison on the best corrected visual acuity improvement in trial group and control group.
Figure 4.Forest plot of comparison on the stereo acuity in trial group and control group. (A) overall analysis; (B) subgroup analysis based on RCTs or Non-RCTs.